title: Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases.
abstract: Tryptase is the major secretory protease of human mast cells and is proposed to be involved in neuropeptide processing and tissue inflammation. Exploration of the biology of tryptase has been hindered by the lack of potent, selective inhibitors. The current study explores the properties of aromatic diamidines as inhibitors of dog and human tryptase. The strongest inhibitors of tryptase in this series are bis(5-amidino-2-benzimidazolyl)methane (BABIM) and (5-amidino-2-benzimidazolyl)-(5-(N,N'-dimethylamidino)-2- benzimidazolyl)methane, which exhibit K(i) values of 1.8 and 1.4 nM, respectively, in blocking the hydrolysis of tosyl-L-Gly-Pro-Lys-4-nitroanilide by human tryptase. These compounds are approximately 10,000-fold more potent than benzamidine, and are the strongest reversible inhibitors of tryptase described to date. Other aromatic mono- and diamidines, including amiloride and pentamidine, are less potent. Nonetheless, they abolish tryptase activity at high inhibitor concentrations. The rank order of tryptase inhibitor potency parallels that of inhibitors tested against trypsin. BABIM, the only highly active member of this series whose potency against other targets has been examined previously, is a far stronger inhibitor of tryptase than of other trypsin-like serine proteases, including those involved with hemostasis, fibrinolysis and the complement system. Therefore, BABIM appears to have selective affinity for tryptase. In addition to inhibiting tryptase-induced hydrolysis of peptide-based chromogenic substrates, BABIM blocks completely the reversal of vasoactive intestinal peptide-induced relaxation of isolated trachea by dog tryptase. Thus, BABIM and related amidines are potent inhibitors of mast cell tryptases that may be useful in exploring mast cell protease biology.
authors.affiliation: Cardiovascular Research Institute, University of California, San Francisco.
authors.forename: G H
authors.initials: GH
authors.lastname: Caughey
authors.forename: W W
authors.initials: WW
authors.lastname: Raymond
authors.forename: E
authors.initials: E
authors.lastname: Bacci
authors.forename: R J
authors.initials: RJ
authors.lastname: Lombardy
authors.forename: R R
authors.initials: RR
authors.lastname: Tidwell
mesh_terms: D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology*; D053818:Chymases; D004285:Dogs; D005289:Ferrets; D006801:Humans; D006868:Hydrolysis; D008297:Male; D008407:Mast Cells / Q000201:enzymology*; D051381:Rats; D012697:Serine Endopeptidases / Q000378:metabolism*; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology*; D013045:Species Specificity; D013329:Structure-Activity Relationship; D053802:Tryptases; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism
chemical_list: D001562:Benzimidazoles; D015842:Serine Proteinase Inhibitors; D014660:Vasoactive Intestinal Peptide; C025426:bis(5-amidino-2-benzimidazolyl)methane; D000584:Amiloride; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; C509223:Tpsab1 protein, rat; C509221:Tpsb2 protein, rat; D053802:Tryptases